Source link : https://www.newshealth.biz/health-news/daily-oral-edaravone-for-als-no-better-than-on-off-regimen/
SAVANNAH, Ga. — Daily oral edaravone (Radicava ORS) was not superior to the FDA-approved on/off regimen in amyotrophic lateral sclerosis (ALS), a phase IIIb trial showed. Both on/off dosing and daily oral edaravone led to similar scores (P=0.777) on the Combined Assessment of Function and Survival (CAFS) at week 48, reported Jeffrey Rothstein, MD, PhD, […]
Author : News Health
Publish date : 2024-10-21 14:45:19
Copyright for syndicated content belongs to the linked Source.